For prostate cancer, CARs binding to the prostate-specific membrane antigen (PSMA), the prostate stem cell antigen (PSCA), and EpCAM have been tested in preclinical and phase I clinical trials [344]. The gene discussed is PSCA; the disease is prostate cancer.